Edition:
United Kingdom

Champions Oncology Inc (CSBR.OQ)

CSBR.OQ on NASDAQ Stock Exchange Capital Market

9.90USD
24 May 2019
Change (% chg)

$0.81 (+8.91%)
Prev Close
$9.09
Open
$8.98
Day's High
$9.93
Day's Low
$8.98
Volume
18,588
Avg. Vol
12,149
52-wk High
$17.89
52-wk Low
$4.07

Latest Key Developments (Source: Significant Developments)

Champions Oncology Reports Q1 Revenue Rose 23.7 Pct To $6.2 Mln
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $6.2 MILLION.Q1 REVENUE ROSE 23.7 PERCENT TO $6.2 MILLION.SEES FY 2019 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC QTRLY GAAP EARNINGS PER SHARE $0.04.CHAMPIONS BIOTECHNOLOGY INC - REITERATED FORECAST OF REVENUE GROWTH IN FISCAL 2019.CHAMPIONS BIOTECHNOLOGY INC QTRLY NON-GAAP EPS $0.05.  Full Article

Champions Oncology QTRLY Loss Per Share GAAP $0.06
Thursday, 26 Jul 2018 

July 26 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD ANNUAL REVENUE EXCEEDING $20M FOR FISCAL YEAR ENDED APRIL 30, 2018.Q4 REVENUE ROSE 32.3 PERCENT TO $4.9 MILLION.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE - GAAP $0.06.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE NON-GAAP $0.04.  Full Article

Champions Oncology Reports Quarterly Revenue Of $5.1 Million
Thursday, 15 Mar 2018 

March 15 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS QUARTERLY REVENUE OF $5.1 MILLION.Q3 REVENUE ROSE 42.6 PERCENT TO $5.1 MILLION.SEES FY 2018 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC QTRLY LOSS PER SHARE ‍$0.01​.  Full Article

Champions Oncology Reports Record Quarterly Revenue Of $5.2 Million
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $5.2 MILLION.Q2 REVENUE ROSE 16.7 PERCENT TO $5.2 MILLION.SEES FY 2018 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC - REITERATED EXPECTATIONS FOR FISCAL YEAR 2018 REVENUE GROWTH OF AT LEAST 20% OVER FISCAL YEAR 2017.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE $0.01.CHAMPIONS BIOTECHNOLOGY - REITERATES POSITION THAT "IT DOES NOT CURRENTLY INTEND TO RAISE CAPITAL IN THE EQUITY MARKET".  Full Article

Champions Biotechnology reports Q1 loss per share $0.06
Thursday, 14 Sep 2017 

Sept 15 (Reuters) - Champions Biotechnology Inc :Champions Oncology reports record quarterly revenue of $5 million.Q1 revenue rose 37.1 percent to $5.0 million.Sees fy 2018 revenue up at least 20 percent.Champions Biotechnology Inc - reiterated expectations for fiscal year 2018 revenue growth of at least 20 pct over fiscal year 2017.Champions Biotechnology Inc qtrly loss per share $0.06.Champions Biotechnology Inc qtrly adjusted loss per share $0.01.  Full Article

Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of PDX models
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models.Champions Biotechnology Inc- ‍cohorts of PDX models will be used in AstraZeneca's Oncology research and development programs in breast and lung cancer​.  Full Article

Champions Oncology to collaborate with Addario Lung Cancer Medical Institute
Friday, 18 Aug 2017 

Aug 18 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces research collaboration with the Addario Lung Cancer Medical Institute to develop unique cohort of patient-derived xenograft (PDX) models.Champions Biotechnology - deal with Addario Lung Cancer Medical Institute "ALCMI" to develop a cohort of PDX models in patients with ROS1 gene rearrangement​.  Full Article